AtriCure, Inc. (ATRC)
| Market Cap | 3.55B |
| Revenue (ttm) | 212.58M |
| Net Income (ttm) | -48.66M |
| Shares Out | 45.63M |
| EPS (ttm) | -1.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $77.67 |
| Previous Close | $77.71 |
| Change ($) | -0.04 |
| Change (%) | -0.05% |
| Day's Open | 77.80 |
| Day's Range | 77.01 - 80.44 |
| Day's Volume | 246,599 |
| 52-Week Range | 34.04 - 80.44 |
AtriCure (ATRC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced U.S. Food and Dr...
AtriCure (ATRC) delivered earnings and revenue surprises of 7.32% and 5.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 11.11% year over year to ($0.32), which beat the ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 20...
AtriCure (NASDAQ:ATRC) announces its next round of earnings this Tuesday, April 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings announcement.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will rel...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
Shares of AtriCure (NASDAQ:ATRC) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 51.35% year over year to ($0.18), which beat the estimat...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2...
On Tuesday, February 23, AtriCure (NASDAQ:ATRC) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will rel...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has rece...
AtriCure (ATRC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2020 Results - Earnings Call Transcript
AtriCure (ATRC) delivered earnings and revenue surprises of 67.65% and 13.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 20...
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will rel...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade i...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2020 Results - Earnings Call Transcript
AtriCure (ATRC) delivered earnings and revenue surprises of 64.29% and 16.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q2 results.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2...
AtriCure, Inc. (ATRC) CEO Michael Carrel on Q1 2020 Results - Earnings Call Transcript
AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q4 2019 Results - Earnings Call Transcript
AtriCure has moved higher as of late, but there could definitely be trouble on the horizon for this company.
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2019 Results - Earnings Call Transcript
AtriCure (ATRC) delivered earnings and revenue surprises of -17.86% and 1.90%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2019 Results - Earnings Call Transcript
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
President, CEO, & Director of Atricure Inc (NASDAQ:ATRC) Michael H Carrel (insider trades) sold 25,000 shares of ATRC on 07/10/2019 at an average price of $32 a share.
AtriCure's (ATRC) CEO Mike Carrel on Q1 2019 Results - Earnings Call Transcript
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About ATRC
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Aug 5, 2005 |
| Stock Exchange NASDAQ | Ticker Symbol ATRC |
Financial Performance
In 2020, AtriCure's revenue was $206.53 million, a decrease of -10.52% compared to the previous year's $230.81 million. Losses were -$48.16 million, 36.8% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for AtriCure stock is "Strong Buy." The 12-month stock price forecast is 82.71, which is an increase of 6.49% from the latest price.